Bibliographic Details
| Title: |
Atrial arrhythmias following CAR‐chimeric antigen receptor T‐cell therapy: Incidence, risk factors and biomarker profile. |
| Authors: |
Shouval, Roni, Goldman, Adam, Flynn, Jessica R., El‐Moghraby, Ahmed, Rehman, Mahin, Devlin, Sean M., Corona, Magdalena, Landego, Ivan, Lin, Richard J., Scordo, Michael, Raj, Sandeep S., Giralt, Sergio A., Palomba, M. Lia, Dahi, Parastoo B., Walji, Moneeza, Salles, Gilles, Nath, Karthik, Geyer, Mark B., Park, Jae H., Fein, Joshua A. |
| Source: |
British Journal of Haematology; Sep2024, Vol. 205 Issue 3, p978-989, 12p |
| Subject Terms: |
DISEASE risk factors, CHIMERIC antigen receptors, CYTOKINE release syndrome, ANTIGEN receptors, ATRIAL arrhythmias, CARDIOTOXICITY |
| Abstract: |
Summary: Recent reports have raised concerns about the association of chimeric antigen receptor T cell (CAR‐T) with non‐negligible cardiotoxicity, particularly atrial arrhythmias. First, we conducted a pharmacovigilance study to assess the reporting of atrial arrhythmias following CD19‐directed CAR‐T. Subsequently, to determine the incidence, risk factors and outcomes of atrial arrhythmias post‐CAR‐T, we compiled a retrospective single‐centre cohort of non‐Hodgkin lymphoma patients. Only commercial CAR‐T products were considered. Atrial arrhythmias were nearly fourfold more likely to be reported after CAR‐T therapy compared to all other cancer patients in the FAERS (adjusted ROR = 3.76 [95% CI 2.67–5.29]). Of the 236 patients in our institutional cohort, 23 (10%) developed atrial arrhythmias post‐CAR‐T, including 12 de novo arrhythmias, with most (83%) requiring medical intervention. Atrial arrhythmias frequently co‐occurred with cytokine release syndrome and were associated with higher post‐CAR‐T infusion peak levels of IL‐10, TNF‐alpha and LDH, and lower trough levels of fibrinogen. In a multivariable analysis, risk factors for atrial arrhythmia were history of atrial arrhythmia (OR = 6.80 [2.39–19.6]) and using CAR‐T product with a CD28‐costimulatory domain (OR = 5.17 [1.72–18.6]). Atrial arrhythmias following CD19‐CAR‐T therapy are prevalent and associated with elevated inflammatory biomarkers, a history of atrial arrhythmia and the use of a CAR‐T product with a CD28 costimulatory domain. [ABSTRACT FROM AUTHOR] |
|
Copyright of British Journal of Haematology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
